First Impressions... - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

First Impressions...


Special from Pharmaceutical Technology


It is clear from my visit that China is on the rise as a center for pharmaceutical R&D, but the trend is still in its early stages. Pharmaceutical companies are still getting their footing for operating in China, and the pharmaceutical services industry still has a lot of maturing to do.

One scene at the Impact China II conference captured the state of affairs for me. On one side of the conference hall sat a five-member team from a major pharmaceutical company that came to explore how its company should establish operations in China. On the other side of the hall sat a senior research scientist who was there at his own expense to determine whether he should accept an offer from a venture capital firm that was recruiting him to lead a CRO start-up.

He worked for the same Big Pharma company that sent the five-member team.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Special from Pharmaceutical Technology,
Click here